Vanguard Capital Management
MLYS icon

Vanguard Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Vanguard Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.4M Buy
2,756,770
+302,407
+12% +$8.3M ﹤0.01% 1716
2026
Q1 		$66.5M Buy
+2,454,363
New +$72M ﹤0.01% 1692

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Capital Management's MLYS Position: Q2 2026 in Review

Vanguard Capital Management increased its Mineralys Therapeutics (MLYS) stake by 12% in Q2 2026, buying an estimated $8.3M and bringing the position to 2,756,770 shares worth $74.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

Vanguard Capital Management first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Vanguard Capital Management held 2,756,770 shares of Mineralys Therapeutics worth $74.4M as of Q2 2026.
  • Vanguard Capital Management bought 302,407 Mineralys Therapeutics shares in Q2 2026, an estimated $8.3M.
  • Mineralys Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1716 holding.
  • Vanguard Capital Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.